EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, has established a dedicated immuno-oncology innovation platform integrating research, early development and biomarker strategies. The new platform will focus on developing therapies that leverage the immune system’s natural ability to fight tumors, and work in combination with existing and future therapies. The new immuno-oncology platform includes therapeutic cancer vaccines, cancer stem cells, and immunotolerance. The portfolio compri...